Cardinal Health, Inc. (CAH) Up 9.5% — Time to Put Skin in the Game?
Cardinal Health, Inc. (CAH) showed strong performance in the latest session, advancing 9.54% to close at $226.58, gaining $19.73 on the day from a previous close of $206.85. This surge pushed the stock decisively into new high ground, moving beyond its prior 52-week peak of $220.27 set just days earlier. Trading action reflects a bullish tone, with CAH extending its climb well above the lower end of its 52-week range at $120.72 and firmly establishing itself at the upper boundary. The move underscores solid upward momentum as the shares continue to gain ground within the health care space.
Despite the strong price advance, trading volume of 714,817 shares came in below the 90-day average of 2,220,451, suggesting that the latest upswing has so far developed without a major spike in activity. Even so, the decisive break to fresh 52-week highs signals strengthening technical momentum, with the stock now trading well beyond its prior ceiling by more than $6. Compared with several major sector peers such as Medtronic (MDT), HCA Healthcare (HCA), and McKesson (MCK), Cardinal Health’s recent price action stands out for its pronounced single-session jump and its clear leadership at the top of its annual range. The stock’s current position reflects an advancing trend that has increasingly separated it from its 52-week low, highlighting sustained bullish activity over the past year.
Why Cardinal Health, Inc. Price is Moving Higher
Cardinal Health, Inc. is rallying on a clear fundamental catalyst: a stronger-than-expected Q2 FY26 earnings report and a material boost to its outlook. The company delivered 19% year-over-year revenue growth to $65.6 billion, with adjusted EPS jumping 36% to $2.63, roughly 10% above consensus estimates. This performance was broad-based, as all major segments posted profit growth above 20%, supported by robust specialty pharmaceutical sales and recent acquisitions such as Solaris. Management reinforced the growth narrative by raising full-year FY26 non-GAAP EPS guidance to a range of $10.15–$10.35, up from $9.65–$9.85 previously, and by signaling stronger profitability in both its Pharmaceutical/Specialty and Global Medical Products businesses.
Investor enthusiasm has translated directly into the stock’s trading action. Shares gapped higher at the open and pushed further intraday, with gains exceeding 9% including premarket, as heavy volume confirmed strong institutional participation. The upgraded earnings outlook, combined with ongoing share repurchases totaling $750 million year-to-date, is amplifying the impact of profit growth on per-share results. On top of that, Wall Street is reinforcing the bullish sentiment: Jefferies recently lifted its price target to $270 with a Buy rating, and the broader analyst community maintains a “Moderate Buy” stance with an average target above the recent trading level. In a Health Care landscape, Cardinal’s double-digit revenue and earnings expansion, along with rising guidance, are helping drive the current upward momentum in its shares.
What is the Cardinal Health, Inc. Rating - Should I Buy?
Weiss Ratings assigns CAH a B rating. Current recommendation is Buy. The stock was upgraded on 3/25/2025. This B rating indicates Cardinal Health, Inc. offers an appealing balance of opportunity and risk for investors seeking exposure to the Health Care space, especially among large, established distributors.
The foundation of this rating is the Excellent Growth Index and Excellent Efficiency Index, a combination that points to a company expanding its operations while making effective use of its capital. Double-digit revenue growth of 22.44% supports the positive growth profile, even as the profit margin remains a modest 0.68%. A forward P/E of 31.22 indicates investors are willing to pay a premium for Cardinal Health, consistent with expectations for continued execution and earnings improvement over time.
On the risk side, the Good Solvency Index and Good Volatility Index indicate a solid financial footing and relatively well-contained price swings compared with more speculative names. The Good Total Return Index shows that shareholders have been reasonably rewarded, which aligns with the recent upgrade and ongoing Buy recommendation. The main area of weakness is the Weak Dividend Index, suggesting that income-focused investors may find more attractive options elsewhere, even though total return prospects remain favorable.
Within its sector, Cardinal Health stands alongside Medtronic plc (MDT, B) and HCA Healthcare, Inc. (HCA, B), while McKesson Corporation (MCK, A-) carries an even higher rating. Overall, CAH’s B rating positions it as a quality, growth-oriented Health Care holding with a risk/reward profile that Weiss Ratings views favorably.
About Cardinal Health, Inc.
Cardinal Health, Inc. is a global healthcare services and products company that plays a central role in the health care equipment and services ecosystem. Through its Pharmaceutical and Specialty Solutions segment, the company distributes a wide range of branded and generic pharmaceuticals, specialty drugs and over-the-counter health and consumer products to hospitals, health systems, retail and mail-order pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and home-based patients. Cardinal Health also supports pharmaceutical manufacturers and healthcare providers with services tailored to specialty therapies, including distribution, program support and logistics, as well as pharmacy management services for hospitals and pharmacies located in community health centers.
Through its Global Medical Products and Distribution segment, Cardinal Health manufactures, sources and distributes an extensive portfolio of Cardinal Health–branded medical, surgical and laboratory products. This includes exam and surgical gloves; needles, syringes and sharps disposal systems; compression, incontinence, nutritional delivery and wound care products; single-use surgical drapes, gowns and apparel; fluid suction and collection systems; urology and operating room supplies; and electrode product lines. The company also distributes a broad range of national brand medical, surgical and laboratory products, provides integrated supply chain services and solutions to healthcare providers, and assembles sterile and non-sterile procedure kits designed to improve efficiency at the point of care.
Cardinal Health further enhances its position in the healthcare value chain by manufacturing, preparing and delivering radiopharmaceuticals, supporting diagnostic imaging and nuclear medicine providers. Its integrated technology solutions help optimize direct shipments and streamline healthcare logistics. Incorporated in 1979 and headquartered in Dublin, Ohio, Cardinal Health has developed into a key partner to healthcare organizations seeking reliable distribution, clinical-quality products and end-to-end supply chain expertise.
Investor Outlook
With a B (Buy) Weiss Rating, Cardinal Health, Inc. (CAH) appears favorably positioned for investors seeking potential for continued gains in the Health Care space. The key watchpoints from here are how the stock behaves around recent trading levels and how broader industry trends influence its risk/reward profile, which underpins the current Buy assessment. See full rankings of all B-rated Health Care stocks inside the Weiss Stock Screener.
--